Table 3.
Anti-spike protein IgG and neutralizing antibodies against live SARS-CoV-2 Delta variant and Omicron variant.
| Day |
Saline |
SCTV01C |
|||
|---|---|---|---|---|---|
| N = 74 | 20 μg, N = 79 | 40 μg, N = 79 | Total N = 158 | ||
| IgG (BAU/mL) | |||||
| Day 0 | GMC (95% CI) | 1711 (1434, 2042) | 1490 (1195, 1857) | 1562 (1320, 1849) | 1525 (1330, 1750) |
| Day 28 | GMC (95% CI) | 1649 (1402, 1940) | 4153 (3526, 4891) | 5354 (4587, 6251) | 4716 (4211, 5281) |
| Fold-Increase (95% CI) | 1.0 (0.9, 1.0) | 2.8 (2.2, 3.6) | 3.4 (2.8, 4.2) | 3.1 (2.6, 3.6) | |
| GMR (95% CI) | 2.6 (2.1, 3.2) | 3.3 (2.7, 4.1) | 2.9 (2.4, 3.5) | ||
| p value | <0.0001 | <0.0001 | <0.0001 | ||
| Delta live virus neutralizing antibody PRNT50 | |||||
| Day 0 | GMT (95% CI) | 1166 (948, 1433) | 901 (666, 1219) | 992 (805, 1224) | 946 (788, 1135) |
| Day 28 | GMT (95% CI) | 1280 (1045, 1567) | 3542 (2922, 4293) | 4112 (3545, 4768) | 3816 (3382, 4305) |
| Fold-Increase (95% CI) | 1.1 (1.0, 1.2) | 3.9 (2.8, 5.5) | 4.1 (3.3, 5.2) | 4.0 (3.3, 5.0) | |
| GMR | 2.9 (2.3, 3.7) | 3.3 (2.6, 4.2) | 3.1 (2.5, 3.8) | ||
| p value | <0.0001 | <0.0001 | <0.0001 | ||
| Omicron live virus neutralizing antibody PRNT50 | |||||
| Day 0 | GMT (95% CI) | 197 (150, 258) | 145 (106, 200) | 212 (161, 278) | 175 (142, 216) |
| Day 28 | GMT (95% CI) | 218 (164, 290) | 640 (520, 788) | 1083 (868, 1352) | 833 (713, 973) |
| Fold-Increase (95% CI) | 1.1 (0.9, 1.3) | 4.4 (3.2, 6.2) | 5.1 (3.9, 6.8) | 4.7 (3.8, 5.9) | |
| GMR (95% CI) | 3.2 (2.4, 4.4) | 4.8 (3.6, 6.5) | 4.0 (3.1, 5.1) | ||
| p value | <0.0001 | <0.0001 | <0.0001 | ||
Fold-Increase = Fold increase over baseline; GMT = Geometric Mean Titer; GMC = Geometric Mean Concentration; GMR = fold increase over control (saline).
p value was calculated by comparison of control group and SCTV01C group, through an ANCOVA model adjusted by log-transformed baseline and interval of vaccination.
For each type of variant, only those with available baseline and post-baseline data are included (iFAS).